Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock

Table 1 Baseline patient characteristics in propensity-matched groups

	PMX-HP (n = 20)	Control (n = 20)	P value
Age, yr	66.7 ± 9.9	67.8 ± 10.2	0.719
Sex, Male, n (%)	12 (60.0)	12 (60.0)	1.000
Underlying malignancy, n (%)	11 (55.0)	12 (60.0)	0.749
Pre-existing organ dysfunction, n (%)	13 (65.0)	13 (65.0)	1.000
Liver insufficiency	1 (5.0)	0 (0.0)	0.311
Chronic respiratory disorder	1 (5.0)	5 (25.0)	0.077
Chronic heart failure	0 (0.0)	2 (10.0)	0.147
Chronic hemodialysis	3 (15.0)	1 (5.0)	0.292
Immunocompromised	3 (15.0)	0 (0.0)	0.072
Use of vasoactive agents
Norepinephrine	18 (90.0)	16 (80.0)	0.376
Dopamine	3 (15.0)	9 (45.0)	0.038
Dobutamine	2 (10.0)	0 (0.0)	0.147
Vasopressin	10 (50.0)	1 (5.0)	0.001
Epinephrine	6 (30.0)	5 (26.3)	0.798
Disease severity
SOFA score	11.2 ± 5.8	10.0 ± 4.0	0.446
APACHE II	19.1 ± 6.5	18.0 ± 4.4	0.534

Results are expressed in mean ± standard deviation; PMX-HP: Polymyxin B hemoperfusion; APACHE II: Acute physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment.